Replies to post #198600 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Can any shed light on whether/why there are apparently “7” censors between 30 and 36 months? Are they new since the prior data share?

[abc1212]

Lykiri, this is truly fanatastic news for the future of GBM treatment.

We have a final group of 108 patients who had their surgery between September 2014 and August 2015. We all know that this is a group of sicker patients. The Germans halved their white blood cell count criteria in the DCVax trial. 83 patients are treatment and 25 are placebo.(83 +25=108)(IMO)

At least 42 patients (93-51) of this sicker group of patients (n=108) had lived to 36 months.
42/108= 38.89 % survival rate at 3 years.

If all these 42 patients are treatment, the Survival rate at 3 years = 50.6%.(42 of a group of 83 dcvax-l patients)

I repeat, if all these 42 patients are treatment, the Survival rate at 3 years = 50.6%.(of this final group of treatment patients)

No wonder Michael Bigger used the words Mind Blown!

Mind Blown! I'll let Dr. Rago explain all of this. I have a Physics degree not a Post Doc in Cancer Genetics from Johns Hopkins #GBM $NWBO

— Michael Bigger (@biggercapital) November 17, 2018

[flipper44]

It appears 49 out of the last 70 that were previously still alive below 36 months back in March 2017 lived beyond 36 months from surgery.

Can we all agree on this?

[doingmybest]

Lykiri,

Thx again for this analysis. One comment I have is that I agree with the belief that it is too coincidental for the 8/15 screening halt not to be related to the lack of 17 control patients, but there was one plausible position (by Rkmatters) that the imbalance may have been caused by the study startup time frame where control patients were not sought or retained.

Does anyone know if there was ever any verification to connect the lack of 17 control pts to the screening halt?

Or, Rkmatters, do you still think the imbalance was caused at the study beginning and not by the screening halt?